Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler

Manufacturers Face New Risk-Management Requirements

REMS to improve the safe use of opioids may lead to controls on other high-risk medicines.
Jul 2, 2009

REMS to improve the safe use of opioids may lead to controls on other high-risk medicines.

FDA Commissioner Hamburg Discusses Drug Regulation

Jun 22, 2009

The new commissioner of the US Food and Drug Administration is mapping plans for turning around an agency that has been demoralized, buffeted about in the press and has lost some of the trust of the American people.

FDA Waves a Big Stick

Agency officials and manufacturers anticipate stricter enforcement of drug safety and quality.
Jun 2, 2009

Agency officials and manufacturers anticipate stricter enforcement of drug safety and quality.

The Comparative-Effectiveness Controversy

Government funding is slated to boost comparative studies of prescription drugs.
May 2, 2009

Government funding is slated to boost comparative studies of prescription drugs.

Downpayment on Health Reform

President Obama's economic recovery plain includes goals such as reducing the number of uninsured citizens and improving the quality of healthcare.
Apr 2, 2009

President Obama's economic recovery plain includes goals such as reducing the number of uninsured citizens and improving the quality of healthcare.

Congress and Obama Seek to Bolster Drug Safety

FDA is poised to gain authority and resources to ensure the quality of food and drugs.
Apr 2, 2009

FDA is poised to gain authority and resources to ensure the quality of food and drugs.

New Leadership and More Resources Aim to Modernize FDA Operations

Mar 19, 2009

Instead of protecting the public from unsafe drugs and contaminated foods, the Food and Drug Administration is a "hazard to public health," stated President Barack Obama in announcing his choices to head the agency and new efforts to improve food safety. Margaret Hamburg will be FDA's new commissioner, and Joshua Sharfstein principal deputy commissioner for drugs and medical products.

A Call for Transparency in Research and Marketing

Broader disclosure of drug prices and conflicts of interest are central healthcare reform issues.
Mar 2, 2009

Broader disclosure of drug prices and conflicts of interest are central healthcare reform issues.

Congress Approves Down Payment on Health Reform

The stimulus bill expands the healthcare safety net while boosting investment in health IT and comparative research.
Feb 19, 2009

The stimulus bill expands the healthcare safety net while boosting investment in health IT and comparative research.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Click here